Iovance Biotherapeutics (IOVA) Stock Price

Iovance Biotherapeutics Inc is primarily active in the biotechnology industry.

The main competitors of Iovance Biotherapeutics Inc in the market include companies like Adaptimmune Therapeutics plc, Kite Pharma Inc, and Novartis AG.

Iovance Biotherapeutics Inc is a biotechnology company specializing in the development of novel cancer immunotherapies. Founded in 2007, the company is at the forefront of harnessing the power of Tumor-Infiltrating Lymphocytes (TILs) to fight various types of cancer. With its innovative cell therapy platform, Iovance aims to address the unmet medical needs of patients and revolutionize cancer treatment. The company has made significant advancements in clinical trials, demonstrating the potential efficacy of TILs in treating advanced melanoma and cervical cancer. Iovance's commitment to improving patient outcomes and its groundbreaking research has positioned it as a prominent player in the rapidly evolving field of immuno-oncology.

Iovance Biotherapeutics Inc, a leading biotechnology company, has achieved several significant milestones. The company successfully completed the pivotal Study LN-144-01 phase 2 clinical trial, demonstrating the efficacy and safety of its tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma patients. Moreover, Iovance obtained Breakthrough Therapy designation from the FDA for LN-145, its TIL therapy for advanced cervical cancer. The company also secured an exclusive license agreement with the National Cancer Institute, reinforcing its innovative research approach. These milestones underscore Iovance Biotherapeutics' commitment to developing groundbreaking immunotherapies and its potential for transforming the treatment landscape for various cancers.

Iovance Biotherapeutics Inc is primarily present in the United States.

Iovance Biotherapeutics Inc is a biotechnology company that focuses on the development and commercialization of cell-based cancer immunotherapies. The company's values revolve around innovation, scientific excellence, and patient-centricity. Iovance Biotherapeutics Inc is committed to pushing boundaries and delivering next-generation therapies to improve patient outcomes. Their corporate philosophy centers on collaboration, transparency, and a passion to make a meaningful impact in the field of oncology. By leveraging their expertise in cellular therapy, Iovance Biotherapeutics Inc aims to address the unmet needs of cancer patients and redefine the treatment landscape.

Analysts currently set an average price target of 8.00 USD for the Iovance Biotherapeutics stock (median: 6.00 USD), implying -42.5 % versus the latest price. The consensus is based on 16 analyst ratings.

Iovance Biotherapeutics Analyst Price Targets 2026

16 analysts currently rate the Iovance Biotherapeutics stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Iovance Biotherapeutics to generate revenue of 414.74 M USD and earnings per share of -0.39 USD.

Iovance Biotherapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Iovance Biotherapeutics share trades at 12.41 EUR (13.91 USD).

The Iovance Biotherapeutics share (IOVA) is listed on 6 stock exchanges, including: NASDAQ (IOVA), London (0JDK.L), Frankfurt (2LB.F), München (2LB.MU), Düsseldorf (2LB.DU).

Iovance Biotherapeutics Inc. specializes in the development and production of innovative cell therapies that can improve the lives of patients with hard-to-treat cancers. The company has two main products in their pipeline - LN-144 and LN-145, which are based on Iovance's proprietary technology platform. The company's cell therapies are based on extracting tumor cells from the patient, which are then cultured and genetically manipulated in the lab. Through this manipulation, these cells can activate the patient's own immune system to attack and destroy cancer cells. The cells are then reintroduced into the patient to allow for targeted and personalized treatment. Iovance Biotherapeutics' core business is to achieve regulatory approval and commercialize these innovative cell therapies, maximizing their global distribution. The company aims to rely on IT support and data analysis to build extensive databases of patient outcomes and gain long-term scientific insights from the treatment with their cell therapies. The company has obtained approval in the US and EU to conduct clinical studies with LN-145, a cell-based therapy for the treatment of recurrent or metastatic cervical cancer. Studies with these therapies have shown successful results in up to 44 percent of patients with advanced disease. The company also aims to rapidly develop and market LN-144 as a cellular therapy for the treatment of melanoma and other solid tumors. Furthermore, the company is also pursuing other initiatives to expand its product offering and global reach. Iovance plans to collaborate with researchers, physicians, and academic institutions to expand its own technology and expertise, thus improving the production and use of CAR-T cells and other cell-based therapies. Iovance Biotherapeutics' business model is tailored to the needs of affected patients searching for new treatment options to fight their cancers. The company relies on its extensive experience in cell therapy manufacturing and its close relationships with the medical community to market and distribute its products globally. Iovance aims to remain a leader in cancer therapy in the long term by expanding its technology and expertise, thereby staying at the forefront of medical research and innovation.

The expected revenue of Iovance Biotherapeutics is 414.74 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Iovance Biotherapeutics is -158.56 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Iovance Biotherapeutics is currently -35.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Iovance Biotherapeutics stock.

The price-to-sales ratio (P/S) of Iovance Biotherapeutics is currently 13.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Iovance Biotherapeutics stock.

The Eulerpool Quality Score for Iovance Biotherapeutics is 4/10.

The ISIN of Iovance Biotherapeutics is US4622601007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Iovance Biotherapeutics is A2DT49. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Iovance Biotherapeutics is IOVA. The ticker symbol is used to trade Iovance Biotherapeutics shares on the stock exchange.